nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Alkylating Activity—Mechlorethamine—lymphatic system cancer	0.496	0.591	CiPCiCtD
Melphalan—Alkylating Activity—Carmustine—lymphatic system cancer	0.344	0.409	CiPCiCtD
Melphalan—SLC22A3—Vincristine—lymphatic system cancer	0.0755	1	CbGbCtD
Melphalan—Hyponatraemia—Vincristine—lymphatic system cancer	0.000182	0.00215	CcSEcCtD
Melphalan—Leukopenia—Teniposide—lymphatic system cancer	0.000182	0.00215	CcSEcCtD
Melphalan—Alopecia—Fludarabine—lymphatic system cancer	0.000181	0.00214	CcSEcCtD
Melphalan—Bone marrow depression—Methotrexate—lymphatic system cancer	0.000179	0.00212	CcSEcCtD
Melphalan—Pancytopenia—Bleomycin—lymphatic system cancer	0.000178	0.00211	CcSEcCtD
Melphalan—Liver disorder—Methotrexate—lymphatic system cancer	0.000177	0.0021	CcSEcCtD
Melphalan—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.000177	0.0021	CcSEcCtD
Melphalan—Liver function test abnormal—Carmustine—lymphatic system cancer	0.000175	0.00207	CcSEcCtD
Melphalan—Chest pain—Teniposide—lymphatic system cancer	0.000173	0.00205	CcSEcCtD
Melphalan—Cardiac arrest—Vincristine—lymphatic system cancer	0.000172	0.00204	CcSEcCtD
Melphalan—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.000171	0.00202	CcSEcCtD
Melphalan—Oedema—Teniposide—lymphatic system cancer	0.000166	0.00196	CcSEcCtD
Melphalan—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000165	0.00196	CcSEcCtD
Melphalan—Anaemia—Fludarabine—lymphatic system cancer	0.000165	0.00195	CcSEcCtD
Melphalan—Infection—Teniposide—lymphatic system cancer	0.000164	0.00195	CcSEcCtD
Melphalan—Stomatitis—Bleomycin—lymphatic system cancer	0.000163	0.00193	CcSEcCtD
Melphalan—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000162	0.00192	CcSEcCtD
Melphalan—Tachycardia—Teniposide—lymphatic system cancer	0.000162	0.00191	CcSEcCtD
Melphalan—Leukopenia—Fludarabine—lymphatic system cancer	0.00016	0.00189	CcSEcCtD
Melphalan—Pruritus—Mechlorethamine—lymphatic system cancer	0.000159	0.00188	CcSEcCtD
Melphalan—Anorexia—Teniposide—lymphatic system cancer	0.000158	0.00187	CcSEcCtD
Melphalan—Cough—Fludarabine—lymphatic system cancer	0.000156	0.00184	CcSEcCtD
Melphalan—Pancytopenia—Carmustine—lymphatic system cancer	0.000156	0.00184	CcSEcCtD
Melphalan—Skin ulcer—Methotrexate—lymphatic system cancer	0.000155	0.00184	CcSEcCtD
Melphalan—Hypotension—Teniposide—lymphatic system cancer	0.000155	0.00183	CcSEcCtD
Melphalan—Convulsion—Fludarabine—lymphatic system cancer	0.000154	0.00183	CcSEcCtD
Melphalan—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000154	0.00182	CcSEcCtD
Melphalan—Neutropenia—Carmustine—lymphatic system cancer	0.000153	0.00181	CcSEcCtD
Melphalan—Myalgia—Fludarabine—lymphatic system cancer	0.000152	0.0018	CcSEcCtD
Melphalan—Haemoglobin—Bleomycin—lymphatic system cancer	0.000151	0.00179	CcSEcCtD
Melphalan—Haemorrhage—Bleomycin—lymphatic system cancer	0.00015	0.00178	CcSEcCtD
Melphalan—Pancytopenia—Vincristine—lymphatic system cancer	0.000148	0.00176	CcSEcCtD
Melphalan—Dyspnoea—Teniposide—lymphatic system cancer	0.000148	0.00175	CcSEcCtD
Melphalan—Neutropenia—Vincristine—lymphatic system cancer	0.000146	0.00173	CcSEcCtD
Melphalan—Oedema—Fludarabine—lymphatic system cancer	0.000146	0.00172	CcSEcCtD
Melphalan—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000146	0.00172	CcSEcCtD
Melphalan—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000145	0.00171	CcSEcCtD
Melphalan—Infection—Fludarabine—lymphatic system cancer	0.000145	0.00171	CcSEcCtD
Melphalan—Decreased appetite—Teniposide—lymphatic system cancer	0.000144	0.00171	CcSEcCtD
Melphalan—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000143	0.0017	CcSEcCtD
Melphalan—Vomiting—Mechlorethamine—lymphatic system cancer	0.000143	0.00169	CcSEcCtD
Melphalan—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000142	0.00169	CcSEcCtD
Melphalan—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000142	0.00169	CcSEcCtD
Melphalan—Stomatitis—Carmustine—lymphatic system cancer	0.000142	0.00169	CcSEcCtD
Melphalan—Rash—Mechlorethamine—lymphatic system cancer	0.000142	0.00168	CcSEcCtD
Melphalan—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000141	0.00168	CcSEcCtD
Melphalan—Flushing—Bleomycin—lymphatic system cancer	0.000139	0.00165	CcSEcCtD
Melphalan—Anorexia—Fludarabine—lymphatic system cancer	0.000139	0.00164	CcSEcCtD
Melphalan—Extravasation—Methotrexate—lymphatic system cancer	0.000139	0.00164	CcSEcCtD
Melphalan—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000137	0.00162	CcSEcCtD
Melphalan—Stomatitis—Vincristine—lymphatic system cancer	0.000136	0.00161	CcSEcCtD
Melphalan—Nausea—Mechlorethamine—lymphatic system cancer	0.000133	0.00158	CcSEcCtD
Melphalan—Alopecia—Bleomycin—lymphatic system cancer	0.000133	0.00157	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000133	0.00157	CcSEcCtD
Melphalan—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000132	0.00157	CcSEcCtD
Melphalan—Jaundice—Mitoxantrone—lymphatic system cancer	0.000132	0.00157	CcSEcCtD
Melphalan—Haemoglobin—Carmustine—lymphatic system cancer	0.000132	0.00156	CcSEcCtD
Melphalan—Urticaria—Teniposide—lymphatic system cancer	0.000132	0.00156	CcSEcCtD
Melphalan—Haemorrhage—Carmustine—lymphatic system cancer	0.000131	0.00155	CcSEcCtD
Melphalan—Paraesthesia—Fludarabine—lymphatic system cancer	0.000131	0.00155	CcSEcCtD
Melphalan—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00013	0.00154	CcSEcCtD
Melphalan—Dyspnoea—Fludarabine—lymphatic system cancer	0.00013	0.00154	CcSEcCtD
Melphalan—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000129	0.00153	CcSEcCtD
Melphalan—Dyspepsia—Fludarabine—lymphatic system cancer	0.000128	0.00152	CcSEcCtD
Melphalan—Ulcer—Methotrexate—lymphatic system cancer	0.000128	0.00151	CcSEcCtD
Melphalan—Decreased appetite—Fludarabine—lymphatic system cancer	0.000126	0.0015	CcSEcCtD
Melphalan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000126	0.00149	CcSEcCtD
Melphalan—Fatigue—Fludarabine—lymphatic system cancer	0.000125	0.00149	CcSEcCtD
Melphalan—Pain—Fludarabine—lymphatic system cancer	0.000124	0.00147	CcSEcCtD
Melphalan—Vasculitis—Methotrexate—lymphatic system cancer	0.000124	0.00147	CcSEcCtD
Melphalan—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000124	0.00146	CcSEcCtD
Melphalan—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.000123	0.00146	CcSEcCtD
Melphalan—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000123	0.00146	CcSEcCtD
Melphalan—Urethral disorder—Vincristine—lymphatic system cancer	0.000123	0.00145	CcSEcCtD
Melphalan—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000122	0.00145	CcSEcCtD
Melphalan—Hypersensitivity—Teniposide—lymphatic system cancer	0.000122	0.00145	CcSEcCtD
Melphalan—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000122	0.00144	CcSEcCtD
Melphalan—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000122	0.00144	CcSEcCtD
Melphalan—Flushing—Carmustine—lymphatic system cancer	0.000122	0.00144	CcSEcCtD
Melphalan—Anaemia—Bleomycin—lymphatic system cancer	0.000121	0.00143	CcSEcCtD
Melphalan—Asthenia—Teniposide—lymphatic system cancer	0.000119	0.00141	CcSEcCtD
Melphalan—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000118	0.0014	CcSEcCtD
Melphalan—Pruritus—Teniposide—lymphatic system cancer	0.000117	0.00139	CcSEcCtD
Melphalan—Arrhythmia—Carmustine—lymphatic system cancer	0.000117	0.00139	CcSEcCtD
Melphalan—Leukopenia—Bleomycin—lymphatic system cancer	0.000117	0.00139	CcSEcCtD
Melphalan—Cystitis—Methotrexate—lymphatic system cancer	0.000117	0.00138	CcSEcCtD
Melphalan—Alopecia—Carmustine—lymphatic system cancer	0.000116	0.00137	CcSEcCtD
Melphalan—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000115	0.00137	CcSEcCtD
Melphalan—Cough—Bleomycin—lymphatic system cancer	0.000114	0.00135	CcSEcCtD
Melphalan—Diarrhoea—Teniposide—lymphatic system cancer	0.000113	0.00134	CcSEcCtD
Melphalan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000113	0.00134	CcSEcCtD
Melphalan—Chest pain—Bleomycin—lymphatic system cancer	0.000111	0.00132	CcSEcCtD
Melphalan—Myalgia—Bleomycin—lymphatic system cancer	0.000111	0.00132	CcSEcCtD
Melphalan—Alopecia—Vincristine—lymphatic system cancer	0.000111	0.00131	CcSEcCtD
Melphalan—Bladder pain—Methotrexate—lymphatic system cancer	0.000109	0.0013	CcSEcCtD
Melphalan—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000109	0.0013	CcSEcCtD
Melphalan—Neoplasm—Methotrexate—lymphatic system cancer	0.000109	0.0013	CcSEcCtD
Melphalan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000109	0.00129	CcSEcCtD
Melphalan—Alopecia—Mitoxantrone—lymphatic system cancer	0.000108	0.00128	CcSEcCtD
Melphalan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000107	0.00127	CcSEcCtD
Melphalan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000107	0.00126	CcSEcCtD
Melphalan—Oedema—Bleomycin—lymphatic system cancer	0.000107	0.00126	CcSEcCtD
Melphalan—Infection—Bleomycin—lymphatic system cancer	0.000106	0.00126	CcSEcCtD
Melphalan—Anaemia—Carmustine—lymphatic system cancer	0.000105	0.00125	CcSEcCtD
Melphalan—Vomiting—Teniposide—lymphatic system cancer	0.000105	0.00125	CcSEcCtD
Melphalan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000104	0.00124	CcSEcCtD
Melphalan—Asthenia—Fludarabine—lymphatic system cancer	0.000104	0.00124	CcSEcCtD
Melphalan—Rash—Teniposide—lymphatic system cancer	0.000104	0.00124	CcSEcCtD
Melphalan—Dermatitis—Teniposide—lymphatic system cancer	0.000104	0.00124	CcSEcCtD
Melphalan—Pruritus—Fludarabine—lymphatic system cancer	0.000103	0.00122	CcSEcCtD
Melphalan—Leukopenia—Carmustine—lymphatic system cancer	0.000102	0.00121	CcSEcCtD
Melphalan—Anorexia—Bleomycin—lymphatic system cancer	0.000102	0.00121	CcSEcCtD
Melphalan—Anaemia—Vincristine—lymphatic system cancer	0.000101	0.00119	CcSEcCtD
Melphalan—Hypotension—Bleomycin—lymphatic system cancer	9.97e-05	0.00118	CcSEcCtD
Melphalan—Diarrhoea—Fludarabine—lymphatic system cancer	9.96e-05	0.00118	CcSEcCtD
Melphalan—Convulsion—Carmustine—lymphatic system cancer	9.89e-05	0.00117	CcSEcCtD
Melphalan—Nausea—Teniposide—lymphatic system cancer	9.83e-05	0.00117	CcSEcCtD
Melphalan—Anaemia—Mitoxantrone—lymphatic system cancer	9.8e-05	0.00116	CcSEcCtD
Melphalan—Leukopenia—Vincristine—lymphatic system cancer	9.75e-05	0.00116	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	9.72e-05	0.00115	CcSEcCtD
Melphalan—Chest pain—Carmustine—lymphatic system cancer	9.71e-05	0.00115	CcSEcCtD
Melphalan—Myalgia—Carmustine—lymphatic system cancer	9.71e-05	0.00115	CcSEcCtD
Melphalan—Paraesthesia—Bleomycin—lymphatic system cancer	9.58e-05	0.00114	CcSEcCtD
Melphalan—Dyspnoea—Bleomycin—lymphatic system cancer	9.51e-05	0.00113	CcSEcCtD
Melphalan—Renal failure acute—Methotrexate—lymphatic system cancer	9.51e-05	0.00113	CcSEcCtD
Melphalan—Leukopenia—Mitoxantrone—lymphatic system cancer	9.5e-05	0.00113	CcSEcCtD
Melphalan—Convulsion—Vincristine—lymphatic system cancer	9.44e-05	0.00112	CcSEcCtD
Melphalan—Oedema—Carmustine—lymphatic system cancer	9.31e-05	0.0011	CcSEcCtD
Melphalan—Decreased appetite—Bleomycin—lymphatic system cancer	9.27e-05	0.0011	CcSEcCtD
Melphalan—Myalgia—Vincristine—lymphatic system cancer	9.27e-05	0.0011	CcSEcCtD
Melphalan—Cough—Mitoxantrone—lymphatic system cancer	9.26e-05	0.0011	CcSEcCtD
Melphalan—Infection—Carmustine—lymphatic system cancer	9.25e-05	0.0011	CcSEcCtD
Melphalan—Vomiting—Fludarabine—lymphatic system cancer	9.25e-05	0.0011	CcSEcCtD
Melphalan—Convulsion—Mitoxantrone—lymphatic system cancer	9.19e-05	0.00109	CcSEcCtD
Melphalan—Rash—Fludarabine—lymphatic system cancer	9.17e-05	0.00109	CcSEcCtD
Melphalan—Dermatitis—Fludarabine—lymphatic system cancer	9.17e-05	0.00109	CcSEcCtD
Melphalan—Pain—Bleomycin—lymphatic system cancer	9.12e-05	0.00108	CcSEcCtD
Melphalan—Thrombocytopenia—Carmustine—lymphatic system cancer	9.12e-05	0.00108	CcSEcCtD
Melphalan—Tachycardia—Carmustine—lymphatic system cancer	9.09e-05	0.00108	CcSEcCtD
Melphalan—Chest pain—Mitoxantrone—lymphatic system cancer	9.03e-05	0.00107	CcSEcCtD
Melphalan—Myalgia—Mitoxantrone—lymphatic system cancer	9.03e-05	0.00107	CcSEcCtD
Melphalan—Anaphylactic shock—Vincristine—lymphatic system cancer	8.89e-05	0.00105	CcSEcCtD
Melphalan—Oedema—Vincristine—lymphatic system cancer	8.89e-05	0.00105	CcSEcCtD
Melphalan—Anorexia—Carmustine—lymphatic system cancer	8.88e-05	0.00105	CcSEcCtD
Melphalan—Infection—Vincristine—lymphatic system cancer	8.83e-05	0.00105	CcSEcCtD
Melphalan—Thrombocytopenia—Vincristine—lymphatic system cancer	8.7e-05	0.00103	CcSEcCtD
Melphalan—Hypotension—Carmustine—lymphatic system cancer	8.7e-05	0.00103	CcSEcCtD
Melphalan—Oedema—Mitoxantrone—lymphatic system cancer	8.66e-05	0.00103	CcSEcCtD
Melphalan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	8.66e-05	0.00103	CcSEcCtD
Melphalan—Nausea—Fludarabine—lymphatic system cancer	8.64e-05	0.00102	CcSEcCtD
Melphalan—Infection—Mitoxantrone—lymphatic system cancer	8.6e-05	0.00102	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	8.48e-05	0.00101	CcSEcCtD
Melphalan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	8.48e-05	0.001	CcSEcCtD
Melphalan—Urticaria—Bleomycin—lymphatic system cancer	8.48e-05	0.001	CcSEcCtD
Melphalan—Anorexia—Vincristine—lymphatic system cancer	8.47e-05	0.001	CcSEcCtD
Melphalan—Tachycardia—Mitoxantrone—lymphatic system cancer	8.45e-05	0.001	CcSEcCtD
Melphalan—Skin disorder—Mitoxantrone—lymphatic system cancer	8.41e-05	0.000997	CcSEcCtD
Melphalan—Paraesthesia—Carmustine—lymphatic system cancer	8.36e-05	0.000991	CcSEcCtD
Melphalan—Hypotension—Vincristine—lymphatic system cancer	8.31e-05	0.000984	CcSEcCtD
Melphalan—Dyspnoea—Carmustine—lymphatic system cancer	8.3e-05	0.000984	CcSEcCtD
Melphalan—Anorexia—Mitoxantrone—lymphatic system cancer	8.25e-05	0.000978	CcSEcCtD
Melphalan—Liver function test abnormal—Methotrexate—lymphatic system cancer	8.1e-05	0.00096	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	8.1e-05	0.00096	CcSEcCtD
Melphalan—Decreased appetite—Carmustine—lymphatic system cancer	8.1e-05	0.000959	CcSEcCtD
Melphalan—Hypotension—Mitoxantrone—lymphatic system cancer	8.09e-05	0.000959	CcSEcCtD
Melphalan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	8.04e-05	0.000953	CcSEcCtD
Melphalan—Paraesthesia—Vincristine—lymphatic system cancer	7.98e-05	0.000946	CcSEcCtD
Melphalan—Pain—Carmustine—lymphatic system cancer	7.96e-05	0.000944	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	7.89e-05	0.000935	CcSEcCtD
Melphalan—Hypersensitivity—Bleomycin—lymphatic system cancer	7.86e-05	0.000932	CcSEcCtD
Melphalan—Paraesthesia—Mitoxantrone—lymphatic system cancer	7.77e-05	0.000921	CcSEcCtD
Melphalan—Decreased appetite—Vincristine—lymphatic system cancer	7.73e-05	0.000916	CcSEcCtD
Melphalan—Dyspnoea—Mitoxantrone—lymphatic system cancer	7.72e-05	0.000915	CcSEcCtD
Melphalan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	7.67e-05	0.00091	CcSEcCtD
Melphalan—Fatigue—Vincristine—lymphatic system cancer	7.66e-05	0.000908	CcSEcCtD
Melphalan—Asthenia—Bleomycin—lymphatic system cancer	7.65e-05	0.000907	CcSEcCtD
Melphalan—Dyspepsia—Mitoxantrone—lymphatic system cancer	7.62e-05	0.000903	CcSEcCtD
Melphalan—Pain—Vincristine—lymphatic system cancer	7.6e-05	0.000901	CcSEcCtD
Melphalan—Pruritus—Bleomycin—lymphatic system cancer	7.55e-05	0.000895	CcSEcCtD
Melphalan—Decreased appetite—Mitoxantrone—lymphatic system cancer	7.53e-05	0.000892	CcSEcCtD
Melphalan—Fatigue—Mitoxantrone—lymphatic system cancer	7.46e-05	0.000885	CcSEcCtD
Melphalan—Pain—Mitoxantrone—lymphatic system cancer	7.4e-05	0.000877	CcSEcCtD
Melphalan—Pancytopenia—Methotrexate—lymphatic system cancer	7.2e-05	0.000854	CcSEcCtD
Melphalan—Neutropenia—Methotrexate—lymphatic system cancer	7.09e-05	0.000841	CcSEcCtD
Melphalan—Urticaria—Mitoxantrone—lymphatic system cancer	6.88e-05	0.000815	CcSEcCtD
Melphalan—Hypersensitivity—Carmustine—lymphatic system cancer	6.86e-05	0.000813	CcSEcCtD
Melphalan—Vomiting—Bleomycin—lymphatic system cancer	6.78e-05	0.000804	CcSEcCtD
Melphalan—Rash—Bleomycin—lymphatic system cancer	6.73e-05	0.000797	CcSEcCtD
Melphalan—Dermatitis—Bleomycin—lymphatic system cancer	6.72e-05	0.000796	CcSEcCtD
Melphalan—Asthenia—Carmustine—lymphatic system cancer	6.68e-05	0.000792	CcSEcCtD
Melphalan—Stomatitis—Methotrexate—lymphatic system cancer	6.59e-05	0.000781	CcSEcCtD
Melphalan—Hypersensitivity—Vincristine—lymphatic system cancer	6.55e-05	0.000776	CcSEcCtD
Melphalan—Hepatobiliary disease—Methotrexate—lymphatic system cancer	6.4e-05	0.000758	CcSEcCtD
Melphalan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	6.38e-05	0.000756	CcSEcCtD
Melphalan—Asthenia—Vincristine—lymphatic system cancer	6.38e-05	0.000756	CcSEcCtD
Melphalan—Diarrhoea—Carmustine—lymphatic system cancer	6.37e-05	0.000755	CcSEcCtD
Melphalan—Nausea—Bleomycin—lymphatic system cancer	6.34e-05	0.000751	CcSEcCtD
Melphalan—Asthenia—Mitoxantrone—lymphatic system cancer	6.21e-05	0.000736	CcSEcCtD
Melphalan—Haemoglobin—Methotrexate—lymphatic system cancer	6.1e-05	0.000723	CcSEcCtD
Melphalan—Diarrhoea—Vincristine—lymphatic system cancer	6.08e-05	0.000721	CcSEcCtD
Melphalan—Hepatitis—Methotrexate—lymphatic system cancer	6.07e-05	0.00072	CcSEcCtD
Melphalan—Haemorrhage—Methotrexate—lymphatic system cancer	6.07e-05	0.00072	CcSEcCtD
Melphalan—Urinary tract disorder—Methotrexate—lymphatic system cancer	6e-05	0.000711	CcSEcCtD
Melphalan—Urethral disorder—Methotrexate—lymphatic system cancer	5.95e-05	0.000705	CcSEcCtD
Melphalan—Diarrhoea—Mitoxantrone—lymphatic system cancer	5.92e-05	0.000702	CcSEcCtD
Melphalan—Vomiting—Carmustine—lymphatic system cancer	5.92e-05	0.000702	CcSEcCtD
Melphalan—Rash—Carmustine—lymphatic system cancer	5.87e-05	0.000696	CcSEcCtD
Melphalan—Dermatitis—Carmustine—lymphatic system cancer	5.87e-05	0.000695	CcSEcCtD
Melphalan—Vomiting—Vincristine—lymphatic system cancer	5.65e-05	0.00067	CcSEcCtD
Melphalan—Rash—Vincristine—lymphatic system cancer	5.61e-05	0.000664	CcSEcCtD
Melphalan—Dermatitis—Vincristine—lymphatic system cancer	5.6e-05	0.000664	CcSEcCtD
Melphalan—Nausea—Carmustine—lymphatic system cancer	5.53e-05	0.000656	CcSEcCtD
Melphalan—Vomiting—Mitoxantrone—lymphatic system cancer	5.5e-05	0.000652	CcSEcCtD
Melphalan—Immune system disorder—Methotrexate—lymphatic system cancer	5.48e-05	0.00065	CcSEcCtD
Melphalan—Mediastinal disorder—Methotrexate—lymphatic system cancer	5.47e-05	0.000648	CcSEcCtD
Melphalan—Rash—Mitoxantrone—lymphatic system cancer	5.46e-05	0.000647	CcSEcCtD
Melphalan—Dermatitis—Mitoxantrone—lymphatic system cancer	5.45e-05	0.000646	CcSEcCtD
Melphalan—Alopecia—Methotrexate—lymphatic system cancer	5.36e-05	0.000636	CcSEcCtD
Melphalan—Nausea—Vincristine—lymphatic system cancer	5.28e-05	0.000626	CcSEcCtD
Melphalan—Nausea—Mitoxantrone—lymphatic system cancer	5.14e-05	0.000609	CcSEcCtD
Melphalan—Anaemia—Methotrexate—lymphatic system cancer	4.88e-05	0.000579	CcSEcCtD
Melphalan—Leukopenia—Methotrexate—lymphatic system cancer	4.73e-05	0.000561	CcSEcCtD
Melphalan—Cough—Methotrexate—lymphatic system cancer	4.61e-05	0.000547	CcSEcCtD
Melphalan—Convulsion—Methotrexate—lymphatic system cancer	4.58e-05	0.000543	CcSEcCtD
Melphalan—Chest pain—Methotrexate—lymphatic system cancer	4.5e-05	0.000533	CcSEcCtD
Melphalan—Myalgia—Methotrexate—lymphatic system cancer	4.5e-05	0.000533	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	4.47e-05	0.00053	CcSEcCtD
Melphalan—Anaphylactic shock—Methotrexate—lymphatic system cancer	4.31e-05	0.000511	CcSEcCtD
Melphalan—Infection—Methotrexate—lymphatic system cancer	4.29e-05	0.000508	CcSEcCtD
Melphalan—Thrombocytopenia—Methotrexate—lymphatic system cancer	4.22e-05	0.000501	CcSEcCtD
Melphalan—Skin disorder—Methotrexate—lymphatic system cancer	4.19e-05	0.000497	CcSEcCtD
Melphalan—Anorexia—Methotrexate—lymphatic system cancer	4.11e-05	0.000487	CcSEcCtD
Melphalan—Hypotension—Methotrexate—lymphatic system cancer	4.03e-05	0.000478	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	3.93e-05	0.000466	CcSEcCtD
Melphalan—Paraesthesia—Methotrexate—lymphatic system cancer	3.87e-05	0.000459	CcSEcCtD
Melphalan—Dyspnoea—Methotrexate—lymphatic system cancer	3.85e-05	0.000456	CcSEcCtD
Melphalan—Dyspepsia—Methotrexate—lymphatic system cancer	3.8e-05	0.00045	CcSEcCtD
Melphalan—Decreased appetite—Methotrexate—lymphatic system cancer	3.75e-05	0.000444	CcSEcCtD
Melphalan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	3.72e-05	0.000441	CcSEcCtD
Melphalan—Fatigue—Methotrexate—lymphatic system cancer	3.72e-05	0.000441	CcSEcCtD
Melphalan—Pain—Methotrexate—lymphatic system cancer	3.69e-05	0.000437	CcSEcCtD
Melphalan—Urticaria—Methotrexate—lymphatic system cancer	3.43e-05	0.000406	CcSEcCtD
Melphalan—Hypersensitivity—Methotrexate—lymphatic system cancer	3.18e-05	0.000377	CcSEcCtD
Melphalan—Asthenia—Methotrexate—lymphatic system cancer	3.09e-05	0.000367	CcSEcCtD
Melphalan—Pruritus—Methotrexate—lymphatic system cancer	3.05e-05	0.000362	CcSEcCtD
Melphalan—Diarrhoea—Methotrexate—lymphatic system cancer	2.95e-05	0.00035	CcSEcCtD
Melphalan—Vomiting—Methotrexate—lymphatic system cancer	2.74e-05	0.000325	CcSEcCtD
Melphalan—Rash—Methotrexate—lymphatic system cancer	2.72e-05	0.000322	CcSEcCtD
Melphalan—Dermatitis—Methotrexate—lymphatic system cancer	2.72e-05	0.000322	CcSEcCtD
Melphalan—Nausea—Methotrexate—lymphatic system cancer	2.56e-05	0.000304	CcSEcCtD
